These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 18200520)

  • 1. Antiangiogenic drugs: current knowledge and new approaches to cancer therapy.
    Mauriz JL; González-Gallego J
    J Pharm Sci; 2008 Oct; 97(10):4129-54. PubMed ID: 18200520
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anti-FGF2 approaches as a strategy to compensate resistance to anti-VEGF therapy: long-pentraxin 3 as a novel antiangiogenic FGF2-antagonist.
    Alessi P; Leali D; Camozzi M; Cantelmo A; Albini A; Presta M
    Eur Cytokine Netw; 2009 Dec; 20(4):225-34. PubMed ID: 20167562
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Angiogenesis and antiangiogenic cancer therapy].
    Pour L; Hájek R; Buchler T; Maisnar V; Smolej L
    Vnitr Lek; 2004 Dec; 50(12):930-8. PubMed ID: 15717808
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Neoplasms and angiogenesis].
    Lewy-Trenda I
    Pol Merkur Lekarski; 2002 Sep; 13(75):225-8. PubMed ID: 12474576
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measuring tumour vascular response to antivascular and antiangiogenic drugs.
    Tozer GM
    Br J Radiol; 2003; 76 Spec No 1():S23-35. PubMed ID: 15456711
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antiangiogenesis beyond VEGF inhibition: a journey from antiangiogenic single-target to broad-spectrum agents.
    Limaverde-Sousa G; Sternberg C; Ferreira CG
    Cancer Treat Rev; 2014 May; 40(4):548-57. PubMed ID: 24360358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current strategies and future directions of antiangiogenic tumor therapy.
    Zhang ZL; Wang JH; Liu XY
    Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai); 2003 Oct; 35(10):873-80. PubMed ID: 14515202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Angiogenesis: potentials for pharmacologic intervention in the treatment of cancer, cardiovascular diseases, and chronic inflammation.
    Griffioen AW; Molema G
    Pharmacol Rev; 2000 Jun; 52(2):237-68. PubMed ID: 10835101
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antiangiogenic cancer therapy.
    Cao Y
    Semin Cancer Biol; 2004 Apr; 14(2):139-45. PubMed ID: 15018898
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular targets on blood vessels for cancer therapies in clinical trials.
    Sato M; Arap W; Pasqualini R
    Oncology (Williston Park); 2007 Oct; 21(11):1346-52; discussion 1354-5, 1367, 1370 passim. PubMed ID: 18080618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antiangiogenic agents in cancer therapy.
    Lenz HJ
    Oncology (Williston Park); 2005 Apr; 19(4 Suppl 3):17-25. PubMed ID: 15934499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synopsis of angiogenesis inhibitors in oncology.
    Ellis LM; Liu W; Fan F; Jung YD; Reinmuth N; Stoeltzing O; Takeda A; Akagi M; Parikh AA; Ahmad S
    Oncology (Williston Park); 2002 May; 16(5 Suppl 4):14-22. PubMed ID: 12102576
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies.
    Leite de Oliveira R; Hamm A; Mazzone M
    Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antiangiogenic therapy.
    Albo D; Wang TN; Tuszynski GP
    Curr Pharm Des; 2004; 10(1):27-37. PubMed ID: 14754403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth.
    Gacche RN; Meshram RJ
    Prog Biophys Mol Biol; 2013 Nov; 113(2):333-54. PubMed ID: 24139944
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antiangiogenic effects of zoledronate on cancer neovasculature.
    Metcalf S; Pandha HS; Morgan R
    Future Oncol; 2011 Nov; 7(11):1325-33. PubMed ID: 22044205
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The therapeutic potential of novel antiangiogenic therapies.
    Scappaticci FA
    Expert Opin Investig Drugs; 2003 Jun; 12(6):923-32. PubMed ID: 12783597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of copper in tumour angiogenesis--clinical implications.
    Nasulewicz A; Mazur A; Opolski A
    J Trace Elem Med Biol; 2004; 18(1):1-8. PubMed ID: 15487757
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor angiogenesis revisited: Regulators and clinical implications.
    Ronca R; Benkheil M; Mitola S; Struyf S; Liekens S
    Med Res Rev; 2017 Nov; 37(6):1231-1274. PubMed ID: 28643862
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Angiogenesis--a new target for future therapy.
    Pandya NM; Dhalla NS; Santani DD
    Vascul Pharmacol; 2006 May; 44(5):265-74. PubMed ID: 16545987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.